A New Contender in the Diabetes Drug Arena

diabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreasdiabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreas

diabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreasdiabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreas

diabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreasdiabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreas